



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** HIV-1 gp120 Monoclonal Antibody (F425 B4e8)

**Catalog Number:** 7626

**Lot Number:** 120131

**Release Category:** C

**Provided:** 100 µg at 1.5 mg/ml in PBS. Purified from tissue culture supernatant by protein G chromatography. The antibody is stable at this concentration. If a less concentrated stock is needed, dilute the material no further than 1 mg/ml.

**Description:** Purified from tissue culture supernatant by protein G chromatography.

**Host:** EBV-transformed B cell x HMMA2.5 TG/O heteromyeloma.

**Titer:** Use at 10-20 µg/ml for flow cytometry.

**Special Characteristics:** Reacts with the base of the V3 loop of gp120; neutralizes primary isolates.

**Recommended Storage:** Once thawed, maintain at 4°C. DO NOT RE-FREEZE. This antibody is highly sensitive to multiple freeze-thaw cycles.

**Contributor:** Dr. Marshall Posner and Dr. Lisa Cavacini.

**Isotype:** IgG<sub>2</sub>, kappa.

**References:** Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. *Virology* 2007;**364**:441-53.

Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, Wilson IA. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. *J Mol Biol* 2008;**377**:660-70.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp120 Monoclonal Antibody (F425 B4e8) from Dr. Marshall Posner and Dr. Lisa Cavacini."

**Requests from commercial organizations should be directed to Jodi Hecht, Technology Ventures Office, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, BR2, Boston, MA 02215. Email: [jehecht@bidmc.harvard.edu](mailto:jehecht@bidmc.harvard.edu).**

**Last Updated**

September 18, 2017

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.